Compositions and methods for treating virus infection
Inventors
Jung, Hoe-Yune • LEE, Heonjong • LEE, Dohyun
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11547737-B2
Publication Date
2023-01-10
Expiration Date
Abstract
Compositions and methods for treating viral infection are disclosed. The compositions contain a combination of zinc and a cyclo(His-Pro), in effective amounts. The composition containing a combination of zinc and a cyclo(His-Pro) can be used to treat viral infections including SARS-CoV-2 infections in mammals.
Core Innovation
The invention describes a method for treating a viral infection in a subject in need thereof by administering an effective amount of a combination of zinc and cyclo(His-Pro) (CHP), wherein the viral infection is caused by SARS-CoV-2. The combination is presented as a pharmaceutical composition for antiviral treatment, and the document further discloses solid-state forms of CHP that are compatible with the zinc/CHP combination approach.
The document addresses the problem of treating SARS-CoV-2 infection by providing a zinc and CHP combination method that can include specific CHP solid-state variants, including anhydrous CHP and crystalline CHP hydrate/monohydrate. Characterization of the crystalline CHP hydrate is linked to X-ray powder diffraction (XRPD) peak positions, and the disclosed forms are supported by stability/purity information in the provided content.
The invention also discloses that the zinc/CHP combination can be used in broader contexts, including preventing and/or treating virally induced conditions caused by SARS-CoV-2. The provided content further indicates optional co-administration with additional antiviral agents (including remdesivir) and/or steroids (including dexamethasone), alongside experimental support showing antiviral/cytoprotection and in vivo lung protection with reduced pathology.
Solid-state conversion and characterization are supported by XRPD-based conversion of Pattern 1 (anhydrous) to Pattern 2 (hydrate) with humidity/temperature effects, using DVS and analytical characterization tools described in the provided content. The experimental support additionally includes in vitro results in Vero cells showing selective antiviral/cytoprotection for Zn+CHP versus single agents or Zn+chloroquine, and an in vivo Syrian hamster SARS-CoV-2 model with reduced pathology compared to vehicle vs Cyclo-Z.
Claims Coverage
The independent claims cover administering zinc plus cyclo(His-Pro) (CHP) to treat SARS-CoV-2 viral infection, and administering zinc plus cyclo(His-Pro) (CHP) to prevent and/or treat SARS-CoV-2-induced virally induced conditions. Across the independent-claim families, the main inventive features include zinc/CHP combination treatment, the SARS-CoV-2 cause, and optional dependent refinements concerning CHP solid-state forms, XRPD-characterized crystalline hydrate, and zinc salt selection and adjunct therapies.
Zinc and CHP combination for SARS-CoV-2 infection treatment
Administering an effective amount of combination of a zinc and a cyclo(His-Pro) (CHP) to the subject for treating a viral infection caused by SARS-CoV-2.
Zinc and CHP combination for preventing and/or treating SARS-CoV-2-induced conditions
Administering an effective amount of combination of a zinc and a cyclo(His-Pro) (CHP) to the subject, wherein the virally induced conditions are caused by SARS-CoV-2, for preventing and/or treating the virally induced conditions.
The independent claims focus on therapeutic and preventive/prophylactic use of a zinc + cyclo(His-Pro) (CHP) combination against SARS-CoV-2, with dependent claim refinements (as reflected in the partial content) supporting specific CHP solid-state forms and XRPD-characterized crystalline hydrate, and further narrowing by zinc salt selection and optional co-administration with additional antiviral agents and/or steroids.
Stated Advantages
Provides antiviral/cytoprotection effects for Zn+CHP versus single agents or Zn+chloroquine, as supported by in vitro results described in the provided content.
Provides in vivo lung protection with reduced pathology in the Syrian hamster SARS-CoV-2 model, as supported by results described in the provided content.
Documented Applications
Treating viral infection caused by SARS-CoV-2 in a subject in need thereof.
Preventing and/or treating virally induced conditions caused by SARS-CoV-2 in a subject in need thereof.
Interested in licensing this patent?